Despite medical advances in recent decades, many treatments are still not as effective as they could be as many patients do not take their medicines as prescribed. Elderly patients may have difficulty in remembering to do so. Chronically ill patients may discontinue taking their medication once they feel better, unaware their disease may recur with severe knock-on effects. The incurred impact linked to poor therapy adherence in the US is estimated around
NXP is launching a solution that helps address this problem. An NFC-enabled sensor is embedded in blister packs or pill bottles and tracks which medication was removed at what time from the package. That information is recorded through the user simply tapping their smartphone to the package. This information can subsequently be used to offer therapy specific and personalized services to support patient, care-giver or healthcare professional.
“The World Health Organisation (WHO) reports that as many as 50 percent of patients experience difficulty following long-term treatment recommendations. These patients suffer as the ineffective treatment will deteriorate their health condition. Public or private payors suffer, as treatments will take longer and become more expensive” commented Bart De Loore, vice president responsible for NXP’s personal health business. “Improving therapy adherence benefits the patient, public and private health budgets and pharma companies who can demonstrate improved patient outcomes. We believe the launch of our therapy adherence platform will help address one of the biggest challenges facing health care systems globally.”
The product value proposition has already been confirmed in the
NXP will collaborate with pharmaceutical and medical packaging companies, application developers, as well as public and private payors to deploy this solution. It will be demonstrated for the first time at
This document includes forward-looking statements which include statements regarding NXP’s business strategy, financial condition, results of operations and market data, as well as other statements that are not historical facts. By their nature, forward-looking statements are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. Readers are cautioned not to place undue reliance on these forward-looking statements. Except for any ongoing obligation to disclose material information as required by
For further press information, please contact:
Europe: Martijn van der Linden+31 6 email@example.com Greater China/ Asia: Esther Chang+886 2 8170 firstname.lastname@example.org Americas: Hillary Cain+1 408 518 email@example.com